Conclusion
Since the approval of dornase alfa in 1993, several drugs have been
developed and approved by regulatory agencies specifically for people
with CF. This process has (so far) culminated in 2020, with approval of
highly-effective modulators for approximately 90% of people with CF
ages 12 years and older. These transformative therapies will surely
reduce morbidity and extend longevity, yet not all people with CF will
have access to these drugs. The therapeutic development pipeline
contains candidate drugs that address many different aspects of disease,
although many face particular challenges to being approved. However, the
challenges of drug development must be met until that time when a
one-time cure is available to all people with CF.